Cerity Partners LLC Increases Position in IQVIA Holdings Inc. (NYSE:IQV)

Cerity Partners LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 3.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 296,759 shares of the medical research company’s stock after purchasing an additional 10,496 shares during the period. Cerity Partners LLC owned about 0.16% of IQVIA worth $70,323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new position in IQVIA during the third quarter valued at $27,000. Park Place Capital Corp purchased a new position in IQVIA during the third quarter valued at $28,000. Versant Capital Management Inc grew its stake in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in IQVIA during the second quarter valued at $27,000. Finally, Itau Unibanco Holding S.A. purchased a new position in IQVIA during the second quarter valued at $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

IQV has been the subject of several research analyst reports. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Wednesday. Morgan Stanley dropped their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, TD Cowen dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Trading Up 2.1 %

Shares of IQV opened at $201.82 on Friday. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a 50-day moving average of $222.67 and a 200 day moving average of $227.16. The firm has a market capitalization of $36.63 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 2.03 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.